In This Week’s Briefing: NYU Launches Psychedelic Training Program, Major Paper Opposes Oregon Legalization,DC Democrats
Similar Posts
![NUMI Stock Deep Dive [ Will Numinus Wellness be a Leader in The Shroom BOOM?] 🤔](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-86-600x338.jpeg)
NUMI Stock Deep Dive [ Will Numinus Wellness be a Leader in The Shroom BOOM?] 🤔
What’s up psychedelic investors! Today we’re finally going to cover the long anticipated NUMIStock. Numinus Wellness is a psychedelic Medicines company using a variety of compounds like psilocybin, MDMA and ketamine to treat for addiction, PTSD, depression and more. You can find the NUMI Stock on the TSX Venture exchange under the ticker symbol NUMI. NUMI stock is currently trading around 1$ Canadian, with a market cap of around $200 million. If you don’t want to purchase NUMI individually, Numinus can also be partially owned through an ETF like Horizons Psychedelic Stock Index or the upcoming Advisor Shares Plant Medicine ETF.
In this video we will cover the problems Numinus is trying to solve, their flagship programs, their financials, and finally the risks for the company. Numinus Wellness is one of the first psychedelic stocks we covered on this channel and the company has advanced quite nicely in the past few months, making it an interesting pick for the shroom boom!
Time Stamps
0:00 – Intro
1:20 – What Problem is Numinus trying to solve?
3:22 – NuMi Ketamine Treatments for Depression
4:50 – MDMA to treat PTSD
6:24 – Numinus Wellness Treating Addiction with Psilocybin
7:48 – Special Access Trials for MDMA and Psilocybin
9:02 – Psilocybin Extraction from Magic Mushrooms
9:39 – Financials and Cash on Hand
11:29 – Risks
https://www.newswire.ca/news-releases/numinus-wellness-closes-q1-2021-with-strong-cash-position-and-industry-firsts-867457159.html?fbclid=IwAR3gKruRdmOGIBZeRmS_xU-R_0J4WehW5TodKLx7SWK19DdpEeoZhM8O-2c#:~:text=Achievedcashbalanceof4915209,(1928737)forQ12021
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
If you want to collaborate, send us an email!
thepsychedelicinvestor@gmail.com
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
…
https://benzinga.grsm.io/thepsychedel
…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#NuminusWellness #NUMIStock #MindMed
MindMed Releases Data on TWO Clinical Trials: A Closer Look Into MMED’s Psilocybin and LSD studies
MindMed Releases Data on TWO Clinical Trials: A Closer Look Into MMED’s Psilocybin and LSD studies.
Mind Medicine (MindMed), (NASDAQ: MNMD, NEO: MMED, DE: MMQ), announced that Dr. Matthias Liechti presented data from several ongoing studies at the INSIGHT Conference in Berlin, Germany, conducted as part of MindMed’s ongoing collaboration with the UHB Liechti Lab.
STUDIES:
https://clinicaltrials.gov/ct2/show/NCT03912974?term=psilocybin+escitalopram&draw=2&rank=2
https://clinicaltrials.gov/ct2/show/NCT03604744?term=LSD+PSilocybin&draw=2&rank=1
https://mindmed.co/news/press-release/mindmed-and-liechti-lab-provide-results-from-their-psilocybin-rd-collaboration/?fbclid=IwAR2_2fUvNf-VTF36Sv6Oz-XB8PTjscqjMWMFF5CKBvKQU2yLMOI_ZP4aq18
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#mindmed #mmed #mnmdstock
Kevin Colley on Career Ending Injury and His Path to Recovery Through Psychedelic-Therapy
Kevin Colley, a former professional hockey player with over a decade of experience, including a stint with the NHL’s New York Islanders, embarked on a profound journey earlier this year. Invited by fellow retired NHL player Riley Cote, Kevin participated in a transformative psychedelic-focused retreat as a patient of WAKE’s clinical program in Jamaica.
Numinus Acquires Novamind: What Does This Mean for the Psychedelic Industry? | NUMI, NM
Numinus Acquiring Novamind in First Major Psychedelics Merger
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Not only will this be your chance to meet me, but also the legendary Paul Stamets!
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Back to Numinus
This acquisition will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.
Psychedelic stock investors woke up to some major news today: Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) announced that they are acquiring Novamind Inc. (CSE: NM) (OTCQB: NVMDF).
The acquisition will be done in stock, and shareholders of Novamind will receive 0.84 of a common share of Numinus per Novamind share held, implying an offer price of $0.44 per Novamind share. This means Numinus is offering a premium of 51% to Novamind shareholders, based on the 20-day volume-weighted average price of their stock. When the transaction is completed, Novamind shareholders will own around 18% of Numinus.
If you currently hold Novamind stock, you do not need to do anything. When the transaction is finalized, each Novamind share you own will automatically be transformed into 0.84 of a Numinus share.
#Numinus #NovaMind #psychedelicStocks
Microdosing VS. Macrodosing Magic Mushrooms feat. Julianne Keu
In today’s interview with Julianne Keu, the famous Microdoser, discusses…
![This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF) CMPS, NUMI, FTPRF, ATAI & CYBN]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-143-600x338.jpeg)
This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF) CMPS, NUMI, FTPRF, ATAI & CYBN]
In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some News on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Numinus Wellness (NUMI), Cybin (CYBN) & Fieldtrip Health (FTPRF).
I covered some breaking news on MindMed yesterday in our impromptu episode on the MindMed stock being added to the EFSE so that mindmed news is not in this episode.
We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.
Timestamps:
0:00 – Intro
0:43 – Australian federal government funds psychedelic research to treat mental illnesses
2:19 – Rhode Island wants to decriminalize all drugs
3:54 – New York Bill to decriminalize psilocybin mushrooms
6:34 – MindMed stock updates ( mmed, mmedf, mmq )
8:17 – Compass Pathways stock news (cmps)
8:49 – Atai Life Sciences news
12:37 – Fieldtrip Health stock news ( ftprf, ftrp)
15:04 – Numinus Wellness stock news ( NUMI, LKYSF)
16:16 – Cybin stock news ( cybn, clxpf)
18:18 General psychedelics discussion
So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks